Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis

Clinical Rheumatology

Volumn 28, Issue 6, 2009, Pages 705-710

  Kerekes, György ^a   Soltész, Pál ^a   Dér, Henriett ^a   Veres, Katalin ^a   Szabó, Zoltán ^a   Végvári, Anikó ^a   Szegedi, Gyula ^b   Shoenfeld, Yehuda ^c   Szekanecz, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Atherosclerosis; Carotid intima media thickness; Endothelial dysfunction; Flow mediated vasodilatation; Lipid profile; Rheumatoid arthritis; Rituximab

Indexed keywords

ADALIMUMAB; ETANERCEPT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; TRIACYLGLYCEROL;

ADULT; ARTERY BLOOD FLOW; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; BRACHIAL ARTERY; CAROTID ARTERY OBSTRUCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG MECHANISM; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BRACHIAL ARTERY; CAROTID ARTERY DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; REGIONAL BLOOD FLOW; TREATMENT OUTCOME; TRIGLYCERIDES; TUNICA INTIMA; TUNICA MEDIA;

EID: 67349230306     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-009-1095-1     Document Type: Article

References (18)

1. Kerekes G, Szekanecz Z, Dér H, Sándor Z, Lakos G, Muszbek L, Csipõ I, Sipka S, Seres I, Paragh G, Kappelmayer J, Szomják E, Veres K, Szegedi G, Shoenfeld Y, Soltész P (2008) Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: A multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 35(3):398-406
2. Giles JT, Post W, Blumenthal RS, Bathon JM (2006) Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nature Clin Pract Rheumatol 2:320-329
3. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Matucci-Cerinic M, Ronda N, Jara LJ, Abu-Shakra M, Meroni PL, Sherer Y (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112:3337-3347
4. Szekanecz Z, Kerekes G, Dér H, Sándor Z, Szabó Z, Végvári A, Simkovics E, Soós L, Szentpétery Á, Besenyei T, Szács G, Szántó S, Tamási L, Szegedi G, Shoenfeld Y, Soltész P (2007) Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci 1108:349-358
5. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126
6. Bergholm R, Leirisalo-Repo M, Vehkavaara S, Makimattila S, Taskinen MR, Yki-Jarvinen H (2002) Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 22:1637-1641
7. Peters MJ, Symmons DPM, McCarey DW, Nurmohamed MT (2008) Cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis: A EULAR task force. Arthritis Rheum 58(9 Suppl):S421
8. Bilsborough W, Keen H, Taylor A, O'Driscoll GJ, Arnolda L, Green DJ (2006) Anti-tumour necrosis factor-α therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 26:1125-1131
9. Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Béchir M, Spieker LE, Neidhert M, Michel BA, Gay RE, Lüscher TF, Gay S, Ruschitzka F (2002) Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106:2184-2187
10. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA (2004) Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor α antibody. Arthritis Rheum 51:447-450
11. Bosello S, Santoliquido A, Zoli A, Di Campli C, Flore R, Tondi P, Ferraccioli G (2008) TNF-α blockade induces a reversible but transient effect of endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol 27:833-839
12. Del Porto F, Lagana B, Lai S, Nofroni I, Tinti F, Vitale M, Podesta E, Mitterhofer AP, D'Amelio R (2007) Response to anti-tumour necrosis factor α blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology 46:1111-1115
13. Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, de Koning M, van de Stadt R, Twisk JW, Dijkmans BA, Lems WF (2005) Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 32:252-255
14. Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA (2006) Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 33:921-923
15. Soubrier M, Jouanel P, Mathieu S, Poujol D, Claus D, Dubost JJ, Ristori JM (2008) Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Jt Bone Spine 75:22-24
16. Oguz FM, Oguz A, Uzunlulu M (2007) The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis. Acta Clin Belg 62:218-222
17. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, Diaz-Varela N, Garcia-Quiroga H, Gonzalez-Gay MA (2008) Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor α blocker therapy. Arthritis Rheum 59:1821-1824
18. Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM (2008) Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 59:222-226